RESUMO
INTRODUCTION
It is often very diffi cult to distinguish infection, which is a microbiological process, from sepsis that is the host reaction to this process. As many as 1 million patients Revista Brasileira de Terapia Intensiva Vol. 19 Nº 2, Abril-Junho, 2007 develop severe sepsis annually in US and more than 300,000 require organ support 1 . Septic shock indeed remains a major cause of death. Therefore, prompt recognition of both the diagnosis and the severity of the disease are essential. The main pro-infl ammatory and anti-infl ammatory cytokines as well as lots of other cellular markers, bioactive circulating molecules or coagulation products are potential biological markers that could help to distinguish the presence of systemic infl ammatory response syndrome (SIRS), disseminated intravascular coagulation (DIC) and sepsis 2 . We aimed to review the main biological markers that could be used nowadays or possibly in the future, either in clinical or research fi elds.
BIOLOGICAL MARKERS
In a simplifi ed way, in sepsis, the mononuclear phagocytes bind to microbial structures through receptors such as CD14 and Toll-like, signaling for the production of some mediators, dependent on the activation of nuclear factor-κB genes 2,3 . Toll-like receptors (TLR) are transmembrane proteins that interact with different agents 4 . The most known are the TLR4 that interacts with the endotoxin; the TLR2 that interacts with the components of the cellular membrane of the gram-positive bacteria; the TLR5 whose ligand is the fl agellin, the main protein component of the fl agella of bacteria, and the TLR3 for the virus. Efforts have been made in understanding the signaling mechanisms of TLR. Inhibition of TLR and proinfl ammatory cytokine signaling highlights new ways for future treatments. There are other receptors that recognize the lypopolysaccaride (LPS), such as CD11/CD18, K + channels and macrophage scavenger receptor. Other soluble and membrane proteins are involved in the recognition of bacteria and its products, such as protein recognition peptidoglicans and triggering receptor expressed on myeloid cells (TREM-1) 5 . TREM-1 may be a potential therapeutic target for septic shock. The determination of the level of a soluble form of TREM-1 (sTREM1) released from the activated macrophages in biological fl uids as plasma or bronchoalveolar lavage help to rapidly identify the presence of infection 6 . Some cytokines are earlier released during the infl ammatory response; interleukin-1 (IL-1) and the tumor necrosis factor-α (TNF). It is followed by the production of other pro-infl ammatory cytokines, such as IL-6, IL-8; and anti-infl ammatory, such as soluble IL-10 and its receptors (IL-2r, TNF55r and TNF75r) 2, 3 . Both the IL-6 and the TNF-α induce the synthesis of acute phase proteins, particularly C-reactive protein (CRP) and the procalcitonin (PCT) 7 . The extreme and prolonged increase of IL-6 circulating level after trauma, burning, SIRS, sepsis and elective surgery is related to morbidity and mortality 8, 9 . After major surgery, a raised IL-6 level in day 1, when associated with signs of SIRS, is an early marker of sepsis 10 . An up-regulation of infl ammatory cytokines production was reported in the earliest stage of sepsis followed by dramatic down-regulation in the phases of severe sepsis or septic shock 11 . An important cytokine protein is the macrophage migration-inhibitory factor (MIF). The MIF plays a role in the modulation of immune response through TLR4 allowing the prompt macrophage response. High levels of MIF have been detected in patients with severe sepsis and septic shock and were associated with microbiologically documented sepsis after cardiac surgery 12, 13 . Another mediator, pre-B-cell colony-enhancing factor may be required for complete expression of the thrombininduced infl ammatory response and has the potential to be a novel marker of acute lung injury and endothelial barrier dysfunction 14 . A protein known as HMGB1 (High Mobility Group Box-1) has been described as a late mediator of infl ammation and sepsis. Patients with sepsis have a high concentration of HMGB 1 up to 1 wk after admission 15 .
COAGULATION MARKERS
The systemic infl ammation is followed by the coagulation system activation 16 . Figure 1 represents the interaction between infl ammation and coagulation. The endothelial injury caused by LPS and pro-infl ammatory cytokines stimulates the production of the tissue factor (TF). The excessive production of thrombin and its inadequate removal by the fi brinolytic system result in widespread intravascular deposition of fi brin characterizing DIC. Routine blood tests do not have the necessary specifi city for DIC diagnosis 17 . DIC dynamics may be better evaluated by measuring markers of the coagulation activation or the secondary fi brinolysis, such as prothrombin fragment 1+2 (F1+2), antithrombin (AT), soluble fi brin (SF), thrombin-antithrombin complex (TAT), and fi brin degradation products (FDP) 18, 19 . The beginning of sepsis is marked by an immediate decline in the activity of factor VIIa followed by a gradual increase in the plasma levels of F1+2 and complex TAT; direct evidence of pro-coagulant state 20 . However, the specifi city of F1+2 for DIC is low once the coagulation process can also be triggered in the extravascular space in the absence of DIC, as in trauma or pancreatitis 21 . The plasma levels of TAT are high in the majority of patients with sepsis even in the absence of clinical signs of DIC, and it is related to multiple organ dysfunction (MOD), shock and death 22 . The TAT high sensitivity can be useful to detect coagulation activation, even at slight degrees; nevertheless its specifi city is limited once increased TAT serum levels can also appear in other clinical situations such as venous thromboembolism. The initial fi brin formation product will be a complex of fi brin monomer with two fi brinogen molecules that will aggregate more molecules and will become insoluble. Thus, it consists of a variety of complexes such as the fi brin-fi brinogen trimolecular complex, the fi brin-FDP complexes, the fi brin-factor XIIIa complexes, and others. The SF is an indicator of continuous intravascular coagulation process once it is only produced in intravascular medium, and remains in circulation for many hours 23 . It was showed a high sensitivity of SF for DIC diagnosis in neurosurgical and critically ill patients 24 . When fi brinogen is converted into fi brin by thrombin, a systemic fi brinolytic, plasmin, cleaves the fi brinogen/fibrin of thrombus originating its degradation products. The D-dimer is a specifi c test for fi brin degradation products. However, high D-dimer serum levels are also found in many clinical situations, such as deep venous thrombosis and pulmonary thromboembolism 25 . A negative serum test for FDP does not exclude the diagnosis of DIC. But in severe sepsis changes in D-dimer serum concentration was an independent predictor of death 20 .
On the other hand, the plasma levels of coagulation natural inhibitors, such as AT and protein C are remarkably reduced in sepsis and septic shock with or without signs of DIC 18, 26 . Mortality rates of 90-100% are described in surgical and septic patients after trauma with AT lower than 70% and 60%, respectively 27 . A reduced AT serum level is a predictor of infection or complicated course in polytraumatized patients 28 . The presence of an AT lower than 54% in the fi rst day of severe sepsis was an independent predictor of death 20 . In severe sepsis more than 80% of the patients have reduced protein C levels. The protein C plasma levels are inversely correlated to mortality 29 . Up to date, the available tests do not present the necessary specifi city for their routine use. Therefore, in the absence of a gold standard the diagnosis of DIC is based on a combination of an appropriate clinical entity known to be associated with DIC, the presence of clinical manifestations, mainly organ dysfunction, and laboratory markers of deranged clotting, such as prolonged clotting times (activated partial thromboplastin time, prothrombin time), and reduced levels of fi brinogen and platelets, and if available an abnormal test for activated clotting such as fi brin degradation products 17 . Other more complex tests are available only in specialized laboratories.
C-REACTIVE PROTEIN
Signifi cant rises in CRP serum concentrations are observed in invasive infections, caused by gram-positive and gram-negative bacteria, as well as systemic fungal infections even in immunodefi cient patients 30 . In contrast, lower increases are observed in acute viral infections. The value of a single CRP measurement in the diagnosis of infection and sepsis was investigated in some studies. It has been show that CRP is an excellent infection marker in patients admitted in the emergency room with a cut-off level of 6 mg/dL (sensitivity = 67%, specifi city = 94% and a ROC curve of 0.88) 29 . On hospital admission, plasma levels of CRP have been over 5 mg/dL in all the patients with community-acquired pneumonia (CAP), and over 10 mg/dL in 75% 32 . CRP serum level is the best predictor of positive cultures after aspirative bronchopneumonia and higher levels are found in patients with pneumonia than in patients with infected bronchitis 33 . Patients presenting maximum daily CRP variation > 4.1 mg/dL plus a CRP level > 8.7 mg/dL had an 88% risk of infection 34 .
In the fi rst 24 hours decreases of CRP over 20% is independently associated with survival and are indicative of infection resolution 35, 36 . Discrete increases in CRP serum concentrations are associated with cardiovascular disease, systemic lupus erythematosus, dermatomyositis, systemic sclerosis, graft versus host disease, and leukemia 37, 38 . However, in response to the infection, these patients are still capable of raising their CRP, distinguishing infection from disease relapse. Signifi cant raises are still observed in major burning, acute pancreatitis and cancer 30 . In these conditions the persistence of high levels has suggested a complicated course and a second increase is highly suggestive of an infectious complication.
CRP serum levels between 5-10 mg/dL have been suggested as cut-off point for diagnosis of sepsis with sensitivity ranging from 71.8% to 98.5%, and specifi city ranging from 47.5% to 75% 39, 40 . High levels of CRP can indicate an evolution with organ dysfunction. In a heterogeneous group of critically ill patients the presence of high concentrations of CRP is related to the presence of organ dysfunction, necessity of dialysis therapy, higher ICU length of stay, and high rates of infection and mortality 41 . Higher CRP concentrations (10 mg/dL) at admission were associated to a particularly raised mortality. A fast decrease was associated to a more favorable evolution. The differential diagnosis between graft rejection and sepsis is frequently diffi cult after organ transplants. The CRP serum levels raises just after liver transplant and reaches the maximum peak in the second day. The maximum CRP levels observed in patients with graft rejection remain low in comparison with increased CRP levels in those with infectious complications 42 . After bone marrow transplant CRP peak was the best independent predictor of a complicated evolution 43 . CRP has negative prognostic value in critically ill patients. Elderly critically ill patients who have not survived presented average CRP serum concentrations at ICU admission signifi cantly higher than the survivors 44 . A good correlation was reported between CRP and two prognostic scores -MPM II (Mortality Predict Model) and APACHE III score 45 . The dynamic serial evaluation of CRP levels is a valuable tool in the diagnosis and follow-up of critically ill patients and can be of great help in the decision of further procedures such as culture sampling, radiology exams or the re-adequacy of antibiotic therapy.
Procalcitonin
The use of PCT as an infection marker has been studied especially in newborn and children, in whom the infection diagnosis is more diffi cult 46 . Slight increases in PCT serum concentrations occur in local bacterial and viral infections besides other conditions as uremia, cardiogenic shock, noninfectious chronic infl ammatory processes and neoplastic diseases 47 . Important increases of PCT are observed in systemic bacterial infections, bacterial meningitis, peritonitis, and septic shock. In a heterogeneous group of critically ill patients a cutoff point of 0.6 ng/mL for PCT was described for the diagnosis of infection 40 . However, in elderly patients high levels might not be indicative of infection 48 . A randomized trial investigating guidance of antibiotic treatment In community-acquired bacterial meningitis a signifi cant decrease in serum PCT was associated with cure 50 . PCT serum levels of 1.3 ± 0.2 ng/mL, 2 ± 0 ng/ mL, 8.7 ± 2.5 ng/mL and 38.6 ± 5.9 ng/mL were reported respectively for SIRS, sepsis, severe sepsis and septic shock 47 . The behavior of the PCT plasma concentrations in patients with acute renal failure is still not well known. However, PCT is better related to the severity of complications in cardiac surgery and trauma patients than CRP 51, 52 .
CONCLUSION
The dosage of the majority of the biological markers is not yet a practical method to be used. Although many markers can identify patients at risk of infection, risk of organ dysfunction, renal failure and other outcomes whether they can be used to guide clinical decisions is not yet very clear. To date sepsis remains a clinical diagnosis. Nevertheless, at the moment, either PCT or the CRP are good markers of infection and sepsis and should be used judiciously to help decisions in the critically ill patient care along with the conventional parameters. Daily, sequential measurement of infl ammatory markers is of much more value to guide therapy. Particularities of the two tests should be taken into consideration. Coagulation markers and sTREM-1 seem to be promising tools to help the management of sepsis.
Abbreviators TLR -Toll-like receptors TREM-1 -triggering receptor expressed on myeloid cells IL -interleukin TNF -tumor necrosis factor-α CRP -C-reactive protein PCT -PCT MIF-macrophage migration-inhibitory factor High Mobility Group Box-1-HMGB1 TF-tissue factor F1+2 -prothrombin fragment 1+2 AT -antithrombin SF -soluble fi brin TAT -thrombin-antithrombin complex FDP -fi brin degradation products
